Emerging treatments
Your Organizational Guidance
ebpracticenet urges you to prioritize the following organizational guidance:
Guide de pratique clinique pluridisciplinaire relatif à la collaboration dans la dispense de soins aux personnes âgées démentes résidant à domicile et leurs aidants prochesPublished by: Groupe de Travail Développement de recommmandations de première ligneLast published: 2017Multidisciplinaire richtlijn voor thuiswonende oudere personen met dementie en hun mantelzorgersPublished by: Werkgroep Ontwikkeling Richtlijnen Eerste Lijn (Worel)Last published: 2017Cilostazol
Cilostazol is a phosphodiesterase III inhibitor which suppresses cyclic adenosine monophosphate (cAMP) degradation. This results in increased cAMP levels in platelets and blood vessels, with antithrombotic and vasodilatory effects. One randomized controlled trial conducted in Japan showed a 39.8% reduction in risk of recurrent stroke in people with a previous lacunar infarction who were treated with cilostazol, compared with placebo.[126] A subsequent trial compared cilostazol with aspirin for prevention of recurrent stroke. Cilostazol was noninferior to aspirin for recurrent stroke prevention, but was associated with a higher incidence of adverse events, including headache, dizziness, tachycardia, palpitations, and diarrhea.[127] Further studies are needed.
Use of this content is subject to our disclaimer